Claris’ plans to sell its generic sterile injectables business may hit roadblock

28 May 2015 Evaluate

Claris Lifesciences’ plans to sell its generic sterile injectables business might hit a block as its site in Ahmedabad has recently received an adverse observation letter from the US Food and Drug Administration (FDA). This site underwent FDA inspection between May 4 and 11.

The facility has received a 483 observation letter, from FDA containing five observations. The report adds these observations relate to insufficient procedures, lacunae in sampling, inadequate training and design deficiencies.

Claris manufactures and markets products across multiple delivery systems, markets, and therapeutic segments including anesthesia, blood products, anti-infectives, and plasma volume expanders. A significant majority of these products are generic drugs that are capable of being directly injected into the human body, which are predominantly used in the treatment of critical illnesses.

 

Peers
Company Name CMP
Redington 274.00
Adani Enterprises 2239.10
Amrapali Industries 15.34
Rashi Peripheral 329.20
PDS 352.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×